Drug Trial Radar · NCT07222137
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 12, 2026
Primary completion
Jul 2031
Study completion Jul 2031
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Oct 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Conditions
- Diabetes Mellitus, Type 1
Interventions
BaricitinibDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from Baseline to Diagnosis of Stage 3 Type 1 DiabetesTime frame: Baseline up to approximately 5 years
Locations
112 sites in 19 countries. Site status is shown where the registry gives one.
Sansum Diabetes Research Institute
Santa Barbara, California · Not yet recruiting
Tallahassee Memorial HealthCare
Tallahassee, Florida · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa · Recruiting
Novak Center for Children's Health
Louisville, Kentucky · Recruiting
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania · Not yet recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Women's and Children's Hospital
Adelaide, Australia · Recruiting
Box Hill Hospital
Box Hill, Australia · Recruiting
Royal Brisbane and Women's Hospital
Brisbane, Australia · Recruiting
Centre for Children's Health Research
Brisbane, Australia · Recruiting
Royal Children's Hospital
Melbourne, Australia · Recruiting
The Royal Melbourne Hospital
Parkville, Australia · Recruiting
Perth Children's Hospital
Perth, Australia · Recruiting
Sydney Children's Hospital
Randwick, Australia · Recruiting
The Children's Hospital at Westmead
Westmead, Australia · Recruiting
UZ Brussel
Brussels, Belgium · Recruiting
Cliniques universitaires Saint-Luc
Brussels, Belgium · Recruiting
Antwerp University Hospital
Edegem, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
CHU UCL Namur/Site Sainte Elisabeth
Namur, Belgium · Recruiting
Freire Pesquisa Clínica
Belo Horizonte, Brazil · Recruiting
Centro de Diabetes Curitiba
Curitiba, Brazil · Recruiting
Hospital Universitario Walter Cantidio
Fortaleza, Brazil · Recruiting
Cendi - Endocrinologia e Diabetes
Goiânia, Brazil · Recruiting
Centro de Pesquisa Clínica de Marília - CPCLIM
Marília, Brazil · Recruiting
Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil · Recruiting
Instituto de Pesquisa Clinica
São Paulo, Brazil · Recruiting
CPCLIN
São Paulo, Brazil · Recruiting
IBTED - Tecnologia e Educação em Diabetes
São Paulo, Brazil · Recruiting
Hospital das Clinicas FMUSP
São Paulo, Brazil · Recruiting
Alberta Children's Hospital
Calgary, Canada · Not yet recruiting
Alberta Diabetes Institute
Edmonton, Canada · Recruiting
BC Diabetes Office
Vancouver, Canada · Recruiting
Oulun yliopistollinen sairaala
Oulu, Finland · Recruiting
Tampereen yliopistollinen sairaala
Tampere, Finland · Recruiting
Turku University Hospital
Turku, Finland · Recruiting
Hospices Civils de Lyon - Hopital Louis Pradel
Bron, France · Not yet recruiting
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France · Not yet recruiting
Hopital Claude Huriez - CHU de Lille
Lille, France · Not yet recruiting
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.